MacroGenics Appoints New Director

Ticker: MGNX · Form: 8-K · Filed: 2024-11-21T00:00:00.000Z

Sentiment: neutral

Topics: board-appointment, governance

Related Tickers: MGNX

TL;DR

Macrogenics adds Dr. Scott Freeman to the board, effective Nov 18, 2024.

AI Summary

On November 18, 2024, MacroGenics, Inc. reported a change in its board of directors. Dr. Scott M. Freeman was appointed as a Class II Director, effective immediately. He will serve until the company's 2027 annual meeting of stockholders and will be a member of the Audit Committee and the Compensation Committee.

Why It Matters

The appointment of a new director can signal a shift in strategic direction or governance for the company, potentially impacting investor confidence and future performance.

Risk Assessment

Risk Level: low — This filing concerns a routine board appointment and does not involve significant financial or operational changes.

Key Players & Entities

FAQ

Who is Dr. Scott M. Freeman and what is his background?

The filing does not provide specific details about Dr. Freeman's background beyond his appointment as a director.

What committees will Dr. Freeman serve on?

Dr. Freeman will serve on the Audit Committee and the Compensation Committee.

When does Dr. Freeman's term as director end?

Dr. Freeman's term will end at the company's 2027 annual meeting of stockholders.

What is the classification of Dr. Freeman's directorship?

Dr. Freeman has been appointed as a Class II Director.

What is the effective date of Dr. Freeman's appointment?

The appointment is effective immediately as of November 18, 2024.

Filing Stats: 641 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2024-11-21 16:32:11

Key Financial Figures

Filing Documents

From the Filing

mgnx-20241118 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 18, 2024 MACROGENICS, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-36112 06-1591613 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 9704 Medical Center Drive Rockville, Maryland 20850 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code: ( 301 ) 251-5172 Not applicable (Former Name or Former Address, if Changed Since Last Report) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.01 per share MGNX Nasdaq Global Select Market Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Resignation of Lynn Cilinski as Vice President, Controller, Treasurer and Principal Accounting Officer On November 18, 2024, Ms. Lynn Cilinski notified MacroGenics, Inc. (the " Company ") of her intention to retire from her position as Vice President, Controller, Treasurer and Principal Accounting Officer, effective January 2, 2025 (the " Effective Date "). The Company thanks Ms. Cilinski for her exemplary service over the past 21 years. Appointment of Beth Smith as Vice President, Controller, Treasurer and Principal Accounting Officer On November 19, 2024, the Board appointed Beth Smith as the Company's Vice President, Controller, Treasurer and Principal Accounting Officer, effective as of the Effective Date. Ms. Smith, age 57, has been with the Company since 2013 in positions of increasing responsibility, culminating as Executive Director of Accounting and Assistant Controller since June 2022. Ms. Smith holds a B.S. in Accounting from Bucknell University. There are no family relationships between Ms. Smith and any of the Company's current or former directors or executive officers. Ms. Smith is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K promulgated under the Securities Act of 1933. As of the filing of this Current Report on Form 8-K (this " Report "), the Company has not entered into any material plan, contract or arrangement to which Ms. Smith is a party or in which she participates in connection with the promotions described above. In the event of such entry into a material plan, contract or arrangement in connection with the promotions described above, the Company will file an amendment to this Report within four business days thereof. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 21, 2024 MACROGENICS, INC. By: /s/ Jeffrey Peters Jeffrey Peters Senior Vice President and General Counsel

View on Read The Filing